TLR7 and COVID-19: Conversely, stimulating PBMCs from severe COVID-19 patients, characterized by rare loss-of-function (LOF) variants of the TLR7 gene, with the TLR7 agonist imiquimod (IMQ), revealed an impaired IFN-I response.